Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue PotentialIncludes Future Optionality to Expand...
Source: marketscreener.com